FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386003149> ?p ?o ?g. }

• W4386003149 endingPage "e006887" @default.
• W4386003149 startingPage "e006887" @default.
• W4386003149 abstract "Background Treatment options are limited for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after treatment failure with EGFR tyrosine kinase inhibitors (TKIs). This multicenter open-label, phase II study aims to evaluate the efficacy and safety of tislelizumab plus chemotherapy (cohort 1, TIS+chemo) or tislelizumab plus chemotherapy and bevacizumab (cohort 2, TIS+chemo+ beva) in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapies. Here, the primary analysis of the TIS+chemo cohort is reported. Methods In the TIS+chemo cohort, patients with EGFR-sensitizing mutations with prior EGFR TKI failure received tislelizumab plus carboplatin and nab-paclitaxel as induction treatment, followed by maintenance with tislelizumab plus pemetrexed. The primary endpoint was 1-year progression-free survival (PFS) rate. The planned sample size was 66 with a historical control of 7%, an expected value of 20%, a one-sided α of 0.05, and a power of 85%. Results Between July 11, 2020 and December 13, 2021, 69 patients were enrolled. As of June 30, 2022, the median follow-up was 8.2 months. Among the 62 patients in the efficacy analysis set, estimated 1-year PFS rate was 23.8% (90% CI 13.1% to 36.2%), and its lower bound of 90% CI was higher than the historical control of chemotherapy (7%), which met the primary endpoint. The median PFS was 7.6 (95% CI 6.4 to 9.8) months. Median overall survival (OS) was not reached (95% CI 14.0 to not estimable), with a 1-year OS rate of 74.5% (95% CI 56.5% to 86.0%). The objective response rate and disease control rate were 56.5% (95% CI 43.3% to 69.0%) and 87.1% (95% CI 76.1% to 94.3%), respectively. Patients who had progressed on first-generation/second-generation and third-generation EGFR-TKIs at baseline had shorter PFS than those who progressed on first-generation/second-generation EGFR-TKIs (median 7.5 vs 9.8 months, p=0.031). Patients with positive ctDNA had shorter PFS (median 7.4 vs 12.3 months, p=0.031) than those with negative ctDNA. No grade 5 treatment-emergent adverse events (TEAEs) were observed. Grades 3–4 TEAEs occurred in 40.6% (28/69) of patients. Grades 3–4 immune-related AEs occurred in 5 (7.2%) patients. Conclusion The study met the primary endpoint for the TIS+chemo cohort. Tislelizumab plus chemotherapy is effective with an acceptable safety profile for EGFR -mutated non-squamous NSCLC after EGFR TKI failure." @default.
• W4386003149 created "2023-08-20" @default.
• W4386003149 creator A5001640465 @default.
• W4386003149 creator A5008206344 @default.
• W4386003149 creator A5014096233 @default.
• W4386003149 creator A5021139793 @default.
• W4386003149 creator A5040579740 @default.
• W4386003149 creator A5040847878 @default.
• W4386003149 creator A5049277287 @default.
• W4386003149 creator A5062851869 @default.
• W4386003149 creator A5074149482 @default.
• W4386003149 creator A5079817705 @default.
• W4386003149 creator A5081882565 @default.
• W4386003149 creator A5084597185 @default.
• W4386003149 creator A5084795769 @default.
• W4386003149 creator A5085409628 @default.
• W4386003149 creator A5086664284 @default.
• W4386003149 creator A5088173296 @default.
• W4386003149 date "2023-08-01" @default.
• W4386003149 modified "2023-10-12" @default.
• W4386003149 title "Tislelizumab plus chemotherapy for patients with<i>EGFR</i>-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy" @default.
• W4386003149 cites W1971243106 @default.
• W4386003149 cites W1987709860 @default.
• W4386003149 cites W2040299716 @default.
• W4386003149 cites W2103441770 @default.
• W4386003149 cites W2112621029 @default.
• W4386003149 cites W2119180969 @default.
• W4386003149 cites W2129590156 @default.
• W4386003149 cites W2132157071 @default.
• W4386003149 cites W2152481222 @default.
• W4386003149 cites W2154662831 @default.
• W4386003149 cites W2155943701 @default.
• W4386003149 cites W2164067249 @default.
• W4386003149 cites W2337209831 @default.
• W4386003149 cites W2337836619 @default.
• W4386003149 cites W2538232731 @default.
• W4386003149 cites W2560717039 @default.
• W4386003149 cites W2770828094 @default.
• W4386003149 cites W2799565954 @default.
• W4386003149 cites W2892640821 @default.
• W4386003149 cites W2899174828 @default.
• W4386003149 cites W2924289105 @default.
• W4386003149 cites W2945998739 @default.
• W4386003149 cites W2946386783 @default.
• W4386003149 cites W2976334328 @default.
• W4386003149 cites W3027428490 @default.
• W4386003149 cites W3109853980 @default.
• W4386003149 cites W3118321568 @default.
• W4386003149 cites W3128021853 @default.
• W4386003149 cites W3128646645 @default.
• W4386003149 cites W3144903047 @default.
• W4386003149 cites W3164993995 @default.
• W4386003149 cites W3177815500 @default.
• W4386003149 cites W3194807048 @default.
• W4386003149 cites W3204380660 @default.
• W4386003149 cites W3205552647 @default.
• W4386003149 cites W4220661685 @default.
• W4386003149 cites W4220798330 @default.
• W4386003149 cites W4280533169 @default.
• W4386003149 cites W4288459215 @default.
• W4386003149 cites W4297982047 @default.
• W4386003149 cites W4303488453 @default.
• W4386003149 cites W4308769053 @default.
• W4386003149 doi "https://doi.org/10.1136/jitc-2023-006887" @default.
• W4386003149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37597849" @default.
• W4386003149 hasPublicationYear "2023" @default.
• W4386003149 type Work @default.
• W4386003149 citedByCount "0" @default.
• W4386003149 crossrefType "journal-article" @default.
• W4386003149 hasAuthorship W4386003149A5001640465 @default.
• W4386003149 hasAuthorship W4386003149A5008206344 @default.
• W4386003149 hasAuthorship W4386003149A5014096233 @default.
• W4386003149 hasAuthorship W4386003149A5021139793 @default.
• W4386003149 hasAuthorship W4386003149A5040579740 @default.
• W4386003149 hasAuthorship W4386003149A5040847878 @default.
• W4386003149 hasAuthorship W4386003149A5049277287 @default.
• W4386003149 hasAuthorship W4386003149A5062851869 @default.
• W4386003149 hasAuthorship W4386003149A5074149482 @default.
• W4386003149 hasAuthorship W4386003149A5079817705 @default.
• W4386003149 hasAuthorship W4386003149A5081882565 @default.
• W4386003149 hasAuthorship W4386003149A5084597185 @default.
• W4386003149 hasAuthorship W4386003149A5084795769 @default.
• W4386003149 hasAuthorship W4386003149A5085409628 @default.
• W4386003149 hasAuthorship W4386003149A5086664284 @default.
• W4386003149 hasAuthorship W4386003149A5088173296 @default.
• W4386003149 hasBestOaLocation W43860031491 @default.
• W4386003149 hasConcept C121608353 @default.
• W4386003149 hasConcept C126322002 @default.
• W4386003149 hasConcept C143998085 @default.
• W4386003149 hasConcept C168563851 @default.
• W4386003149 hasConcept C203092338 @default.
• W4386003149 hasConcept C2776256026 @default.
• W4386003149 hasConcept C2776694085 @default.
• W4386003149 hasConcept C2777240266 @default.
• W4386003149 hasConcept C2777802072 @default.
• W4386003149 hasConcept C2778239845 @default.
• W4386003149 hasConcept C2779438470 @default.
• W4386003149 hasConcept C2781451048 @default.

• next